A detailed history of Rhumbline Advisers transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Rhumbline Advisers holds 7,709 shares of HCM stock, worth $110,238. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,709
Previous 7,553 2.07%
Holding current value
$110,238
Previous $129,000 16.28%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$16.03 - $20.31 $2,500 - $3,168
156 Added 2.07%
7,709 $150,000
Q2 2024

Aug 01, 2024

BUY
$16.36 - $21.78 $9,227 - $12,283
564 Added 8.07%
7,553 $129,000
Q1 2024

May 09, 2024

BUY
$12.08 - $18.56 $954 - $1,466
79 Added 1.14%
6,989 $117,000
Q4 2023

Feb 08, 2024

SELL
$16.25 - $20.23 $19,402 - $24,154
-1,194 Reduced 14.73%
6,910 $125,000
Q2 2023

Aug 08, 2023

BUY
$10.78 - $17.73 $87,361 - $143,683
8,104 New
8,104 $97,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.